Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy.

CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng. The phase 1 study is to evaluate the safety, tolerability, and pharmacokinetics of CB03 in healthy subjects.

"The successful completion of the first human administration of CB03 in the United States is a small but critical step in the clinical development of CB03 and an important milestone in its global clinical development." Said Dr. Huanming Chen, President and Chief Executive Officer of Zhimeng, "CB03 is the first drug candidate of Zhimeng to enter clinic trials in the area of central nervous system diseases. We hope that through our unremitting efforts, we can provide safer and more effective medicines to patients worldwide and improve their quality of live."

About CB03

Studies on the pathogenesis of epilepsy have shown that the imbalance between neuronal excitation and inhibition is the major underlying mechanism associated with alterations in ion channels, synaptic transmission and connections. As the structural basis of neuronal excitability and activity, ion channels dysfunctions are bound up with the development of epilepsy. As the most widely distributed and the most diverse group of ion channels, potassium (K+) channels are mainly involved in the modulation of neuronal excitability and the frequency and amplitude of action potential discharges. K+ channels alterations have been known to be associated with benign familial neonatal convulsions (BFNC) and severe epileptic encephalopathies. KCNQ2/3 potassium ion opener is not only used in the treatment of refractory epilepsy, but also for major depression (MDD), amyotrophic lateral sclerosis (ALS), neuropathic pain and other diseases

Retigabine (Potiga, Ezogabine/Retigabine) was the first KCNQ2/3 potassium channel opener approved by the FDA and EMA in 2011 for the treatment of refractory epilepsy, to which other drugs were ineffective. Unfortunately, retigabine was withdrawn from the market in 2017 because of the risk of vision impairment induced by hyperpigmentation.

CB03 is a new generation of KCNQ2/3 potassium channel opener. Compared with retigabine, it shows better chemical and metabolic stability, antiepileptic activity, pharmacokinetic properties, and safety. Moreover, CB03 has a more specific ion channel selectivity and is unlikely to present the same safety concerns as retigabine.

About Epilepsy

Epilepsy is a central nervous system disorder elicited by excessive discharge of cerebral neurons, afflicting approximately 50 million people worldwide, including nearly 9 million patients in China. Unfortunately, existing antiepileptic treatments are far from meeting the clinical needs of epilepsy patients, and about 30% of epilepsy patients are suffering from refractory epilepsy which cannot be controlled by a single drug.

About Zhimeng

Zhimeng is a clinical-stage biopharmaceutical company committed to developing innovative drugs for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with significant unmet medical needs. The company has recently announced the successful completion of the phase Ib clinical trial on its novel HBV capsid inhibitor, Canocapavir (ZM-H1505R), and plans to kick off the phase II study in June 2022.  In addition, the clinical trial application of the company's TLR8 agonist (CB06) was approved by the FDA in December 2021, and the phase I study was launched in the United States in March 2022.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com

SOURCE Shanghai Zhimeng Biopharma, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED